TSH Biopharm Past Earnings Performance
Past criteria checks 4/6
TSH Biopharm's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 15.8% per year. TSH Biopharm's return on equity is 7.1%, and it has net margins of 9.4%.
Key information
-0.7%
Earnings growth rate
-0.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 15.8% |
| Return on equity | 7.1% |
| Net Margin | 9.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How TSH Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 932 | 88 | 334 | 25 |
| 31 Mar 24 | 867 | 92 | 310 | 25 |
| 31 Dec 23 | 811 | 62 | 311 | 25 |
| 30 Sep 23 | 838 | 54 | 353 | 35 |
| 30 Jun 23 | 826 | 55 | 350 | 34 |
| 31 Mar 23 | 765 | 53 | 323 | 33 |
| 31 Dec 22 | 741 | 62 | 293 | 31 |
| 30 Sep 22 | 450 | 68 | 180 | 14 |
| 30 Jun 22 | 437 | 60 | 174 | 20 |
| 31 Mar 22 | 432 | 57 | 171 | 21 |
| 31 Dec 21 | 413 | 47 | 168 | 24 |
| 30 Sep 21 | 431 | 47 | 172 | 32 |
| 30 Jun 21 | 432 | 53 | 175 | 28 |
| 31 Mar 21 | 418 | 48 | 177 | 29 |
| 31 Dec 20 | 448 | 62 | 182 | 29 |
| 30 Sep 20 | 442 | 53 | 189 | 32 |
| 30 Jun 20 | 473 | 83 | 197 | 42 |
| 31 Mar 20 | 503 | 84 | 205 | 47 |
| 31 Dec 19 | 508 | 85 | 206 | 53 |
| 30 Sep 19 | 502 | 89 | 200 | 59 |
| 30 Jun 19 | 482 | 52 | 185 | 63 |
| 31 Mar 19 | 503 | 50 | 178 | 91 |
| 31 Dec 18 | 516 | 58 | 176 | 97 |
| 30 Sep 18 | 521 | 63 | 173 | 97 |
| 30 Jun 18 | 536 | 73 | 172 | 100 |
| 31 Mar 18 | 521 | 85 | 175 | 76 |
| 31 Dec 17 | 486 | 65 | 172 | 74 |
| 30 Sep 17 | 497 | 58 | 176 | 89 |
| 30 Jun 17 | 475 | 42 | 179 | 89 |
| 31 Mar 17 | 485 | 98 | 173 | 110 |
| 31 Dec 16 | 492 | 141 | 174 | 116 |
| 30 Sep 16 | 487 | 165 | 187 | 121 |
| 30 Jun 16 | 505 | 176 | 189 | 120 |
| 31 Mar 16 | 506 | 127 | 191 | 106 |
| 31 Dec 15 | 514 | 83 | 194 | 106 |
| 30 Sep 15 | 531 | 59 | 193 | 93 |
| 30 Jun 15 | 546 | 55 | 201 | 99 |
| 31 Mar 15 | 554 | 59 | 213 | 89 |
| 31 Dec 14 | 562 | 74 | 213 | 86 |
| 30 Sep 14 | 565 | 81 | 192 | 97 |
| 30 Jun 14 | 582 | 97 | 196 | 93 |
| 31 Mar 14 | 585 | 104 | 194 | 93 |
| 31 Dec 13 | 597 | 110 | 195 | 87 |
Quality Earnings: 8432 has high quality earnings.
Growing Profit Margin: 8432's current net profit margins (9.4%) are higher than last year (6.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8432's earnings have declined by 0.7% per year over the past 5 years.
Accelerating Growth: 8432's earnings growth over the past year (59.5%) exceeds its 5-year average (-0.7% per year).
Earnings vs Industry: 8432 earnings growth over the past year (59.5%) exceeded the Pharmaceuticals industry 11.9%.
Return on Equity
High ROE: 8432's Return on Equity (7.1%) is considered low.